Patient care at Weill Cornell Medicine has not been materially impacted by a technology outage. READ MORE HERE

Ruben Niesvizky, M.D.

Medical Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

As the Director of the Multiple Myeloma Center at New York Presbyterian Hospital-Cornell Medical Center, my duties will focus on providing outstanding clinical care and coordinating a world class clinical translational research program. Prestigious investigators have joined forces to create one of the leading centers for myeloma research. I have no doubt that this cooperative effort forms one of the best myeloma research groups on the World.

My 25 years of experience as a myeloma physician has helped me to appreciate how important it is to treat patients in the context of a comprehensive and individualized program. New York Presbyterian Hospital has an outstanding Bone Marrow Transplant Service (a treatment modality often used for myeloma patients), performing more than 100 transplants per year. It has also been rated the best in the world in the fields of cardiology (heart), neurosurgery and nephrology (kidney). The Hospital for Special Surgery, also part of the New York Presbyterian-Weill Cornell system, has an outstanding group of orthopedic surgeons that support a new comprehensive bone disease program. In addition, as part of our continuing search for more effective therapeutic options, we offer multiple clinical trials utilizing promising new drugs and medical procedures for treating myeloma and related hematological disorders.

The ultimate goal is to find the cure for multiple myeloma. The establishment of a free standing Multiple Myeloma Center at New York Presbyterian Hospital Weill Cornell Medical Center is an important step towards the accomplishment of this goal.

For more information, please click here: http://www.Myelomacenter.org

Biographical Info

Dr. Niesvizky is Professor of Medicine at Weill Cornell Medical College and at NewYork Presbyterian Hospital/Weill Cornell Medical Center in Manhattan. He also serves as Director of the Multiple Myeloma Center at NewYork Presbyterian Hospital/Weill Cornell Medical Center. After receiving a medical degree from National University of Mexico, Dr. Niesvizky did a research fellowship in cell biology-granulocytopoiesis and an internal medicine residency at the National Institute of Nutrition in Mexico. He then completed fellowships in New York: one (hematology) at Mount Sinai Medical Center and one (hematology/medical oncology) at Memorial Sloan-Kettering Cancer Center. He has written more than 100 articles, editorials, chapters, and abstracts published in journals such as New England Journal of Medicine, Blood and Leukemia & Lymphoma, most recently on topics such as the treatment of myeloma and Waldenstrom's macroglobulinemia. He is the recipient of various grants and awards from the National Cancer Institute and the Leukemia and Lymphoma Society, including a K23 award and three translational research grants. He received the 2007 Investigator Award of the Michael Wolk Heart Foundation. He has been voted by pears as “Best Doctors” in 2013 and appeared in New York Magazine as Hematolgy “Top Doctors” 2014. A frequent lecturer, Dr Niesvizky regularly presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which he is also a member. He is an active member of the International Myeloma Working Group which defines standards of research and practice in myeloma. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.

Honors and Awards

2001-2005: The Leukemia and Lymphoma Society SCOR grant. Clinical Core. 

Translational Research Grant: Awarded by CTEP:NCI. RFP S03-058 SAIC-Frederick

K23 Award: 1 K23 CA109260-01.EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA

2007 Investigator Award of the Michael Wolk Heart Foundation

2014: New York Magazine: Top Doctors

2015: Top Doctors for Cancer, Newsweek Magazine

2016, 2017: America's Top Doctors, Castle Connolly

2016, 2017: America's Top Doctors for Cancer, Castle Connolly

2016, 2017: Top Doctors New York Metro Area, Castle Connolly

America's Top Doctors: 14th Edition 

America's Top Doctors for Cancer: 10th Edition 

Top Doctors: New York Metro Area: 18th Edition

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Hematology)
Clinical Expertise
Amyloidosis
Castleman's Disease
Lymphoma
Macroglobulinemia
Monoclonal Gammopathy of Undetermined Significance
Myeloma
Multiple Myeloma
Plasma Cell Dyscrasia
Plasma Cell Leukemia
Plasma Cell Myeloma
POEMS Syndrome
Smoldering Myeloma
Waldenstrom's Disease
Waldenstrom's Macroglobulinemia
Languages
English
Spanish
Hebrew
Yiddish
Education 
  • M.D.
    National Autonomous University of Mexico, Faculty of Medicine (Mexico)
    1985
Appointments 
  • Attending Physician
    NewYork-Presbyterian Hospital
  • Professor of Medicine
    Weill Cornell Medical College, Cornell University
Videos

Multiple Myeloma Cancer Center NY | Weill Cornell Medicine Multiple Myeloma Center

Plasma Cell Myeloma Cancer Clinical Trials NY | Weill Cornell Medicine Multiple Myeloma Center

Ruben Niesvizky, M.D.

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Consultant: 
Amgen, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Janssen Pharmaceutical Company
Karyopharm Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
Advisory/Scientific Board Member: 
Bristol-Myers Squibb Company
Celgene Corporation
Janssen Pharmaceutical Company
Millennium Pharmaceuticals, Inc.